<?xml version="1.0" encoding="UTF-8"?>
<p>A(H3N2) viruses particularly have serious problems such as low replication efficiency in embryonated hen eggs and critical antigenic alterations during egg adaptation.
 <xref rid="irv12694-bib-0019" ref-type="ref">19</xref>, 
 <xref rid="irv12694-bib-0020" ref-type="ref">20</xref> Recently, the US‐FDA approved an influenza vaccine with cell‐derived seed virus.
 <xref rid="irv12694-bib-0021" ref-type="ref">21</xref> It is thus expected that a completely cell‐based A(H3N2) vaccine will pave the way to overcome the difficulties associated with egg‐based vaccines.
</p>
